Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings
Home
>
Haematology
>
ASH 2022
ASH 2022
American Society of Hematology
10–13 December 2022 New Orleans, LA, USA
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands
ASH 2022 Highlights Podcast
Presented By
Robert van den Heuvel, Medicom
Acute Lymphoblastic Leukaemia
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
Presented By
Prof. Mark Litzow, Mayo Clinic, MN, USA
High-dose methotrexate or standard interim maintenance in young patients with ALL?
Presented By
Ms Amy Kirkwood, University College London, UK
Acute Myeloid Leukaemia
Excellent results for triplet regimen in FLT3-mutated AML
Presented By
Prof. Nicholas Short, University of Texas, TX, USA
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML
Presented By
Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK
Promising results for triplet therapy with magrolimab in AML
Presented By
Prof. Naval Daver, Anderson Cancer Center, TX, USA
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?
Presented By
Prof. Matthias Stelljes, University of Muenster, Germany
Chronic Leukaemia
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL
Presented By
Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA
Ibrutinib plus venetoclax displays long-term benefits in CLL
Presented By
Prof. John Allan, Weill Cornell Medicine, NY, USA
Multiple Myeloma
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data
Presented By
Prof. Ajai Chari, Mount Sinai School of Medicine, NY, USA
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial
Presented By
Prof. Nizar Bahlis, University of Calgary, Canada
Deep and durable responses for quadruple therapy in smouldering MM
Presented By
Prof. Shaji Kumar, Mayo Clinic, MN, USA
Ultra-sensitive MRD assessment in MM with BloodFlow
Presented By
Dr Laura Notarfranchi, University of Parma, Italy
CAR-Hematotox score proves useful in relapsed/refractory MM
Presented By
Dr Kai Rejeski, LMU Munich, Germany
Head-to-head: VMP versus Rd in transplant-ineligible MM
Presented By
Dr Sara Bringhen, Università degli Studi di Torino, Italy
Lymphoma
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma
Presented By
Prof. Martin Dreyling, University Hospital Munich, Germany
High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma
Presented By
Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany
Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Presented By
Prof. Won-Seog Kim, Samsung Medical Center, South Korea
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma
Presented By
Dr Yago Nieto, University of Texas, TX, USA
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL
Presented By
Dr Kai Rejeski, LMU Munich, Germany
Myeloproliferative Neoplasms
Efgartigimod successful in immune thrombocytopenia
Presented By
Prof. Catherine Broome, Georgetown University, Washington DC, USA
INCA033989: novel investigational agent for CALR-mutated MPN
Presented By
Dr Edimara Reis, Incyte Corporation, DE, USA
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN
Presented By
Dr Nabih Maslah, Université Paris Cité, France
Immune Thrombocytopenia
Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia
Presented By
Dr Nardeen Ayad, Massachusetts General Hospital, MA, USA
Various Topics
C1 inhibitor deficiency linked to thrombosis
Presented By
Dr Steven Grover, University of North Carolina, NC, USA
Durable responses to gene therapy in haemophilia A
Presented By
Prof. Stacy Croteau, Harvard Medical School, MA, USA
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia
Presented By
Prof. Mark Walters; Prof. Franco Locatelli
Neutrodiet: non-restricted diet is the preferred option after SCT
Presented By
Prof. Federico Stella, Università degli Studi di Milano, Italy
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care
Presented By
Prof. Régis de Latour, Saint-Louis Hospital, France
Novel therapy may replace standard-of-care prophylaxis for GVHD
Presented By
Prof. Shernan Holtan, University of Minnesota, MN, USA
LMWH does not result in higher live birth rates in women with inherited thrombophilia
Presented By
Prof. Saskia Middeldorp, Radboud UMC, the Netherlands